12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Levomilnacipran: Phase III data

Top-line data from a double-blind, flexible-dose, U.S. Phase III trial in 442 patients aged 18-80 with MDD showed that levomilnacipran met the primary endpoint of improving MADRS-CR total score from baseline to week 8 vs. placebo. Specifically, the placebo-corrected difference in mean change from baseline to week 8 in MADRS-CR total score was 3.1 points (p=0.005). Levomilnacipran also met the secondary endpoint of improving SDS score from baseline to week 8...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >